Mitsubishi Tanabe to Focus on US Approval for VLP Seasonal Flu Vaccine; Aims at 100 Billion Yen Sales for Vaccine Business by FY2030

Seiichi Murakami, head of Ikuyaku Integrated Value Development Division Mitsubishi Tanabe Pharma plans to allocate resources on a priority basis to a seasonal influenza vaccine currently in a PIII clinical study in the US and Canada, and will do its...read more